July 29, 2026

Nichi-In Centre for Regenerative Medicine (NCRM), an unit of  MediNippon Healthcare Pvt. Ltd., an Indo-Japan healthcare company, the R & D collaborator of GN Corporation Co. Ltd., Japan, will present nearly two decades of collaborative translational research at an international webinar to be hosted by SMC Laboratories, Inc., Japan, on 21 August 2026. The webinar will highlight the outcome of a unique translational research ecosystem established through sustained collaboration among scientists, clinicians, academic institutions and industry partners in India, Japan and other countries, yielding novel solutions in healthcare based on original technologies from Japan. 

The webinar will showcase three representative innovations arising from this approach:  

Innovation 1: Providing a solution to Physicians from a basic science technology: BEES-HAUS & BHES-HAUS 

Urologists looking forward to a long term disease recurrence-free solution for male urethral stricture when approached us, we found a synergy with our tissue engineering platform using Festigel scaffold and developed BEES-HAUS (Buccal epithelium Expanded and Encapsulated in Scaffold‐Hybrid Approach to Urethral Stricture) cell therapy. A pilot clinical study was successfully completed. Pre-clinical proof of cell engraftment was also undertaken and the technology was subsequently transferred to Japan. The BEES-HAUS was further simplified as BHES-HAUS (Buccal Epithelium Hashed and Encapsulated in Scaffold – Hybrid Approach to Urethral Stricture), a single sitting procedure incorporating Festigel scaffold, whose encouraging outcome was presented at the American Urology Association (AUA) meeting 2026. BHES-HAUS has a global market potential of 2 billion US dollars. 

Innovation 2: Value adding a food supplement to make it a drug-adjuvant for a rare disease 

Our global network of physician-scientists upon studying the properties of two forms of exo-polysaccharide beta glucans approved as food supplements in Japan, whose dosage had been standardized like that of a drug, compared their specific efficacies in phased pre-clinical studies taking the expertise of SMC laboratories and discovered the immune modulating potentials of one of the products which led to the development of a safe and efficacious disease modifying adjuvant for Duchenne Muscular Dystrophy (DMD), a rare and progressive genetic disorder.  This product has now  received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. FDA. 

Innovation 3: Clinical translation of an implant in a suitable rare disease patient: STAR-MING 

For an ultra-rare disease of Parry Romberg Syndrome with hemi-facial atrophy when an oral and maxillofacial surgeon was looking for a bio inert non-immunogenic non-antigenic non-biodegradable filler until the time when the patient have to undergo a final surgical correction procedure after epiphyseal fusion, found a synergy with our STAR-MING implant. The STAR-MING implant can be cut into an size and can be inserted using a very small incision because 3D printed materials may require large incisions, which on face might be disfiguring and hence they opted for STAR-MING. A clinical study was undertaken with more than nine years follow up proving the safety and efficacy of the STAR-MING implant. The STAR-MING as a facial aesthetic filler and future as a breast implant has a global market potential of Three billion US Dollars. 

About NCRM & MediNippon Healthcare Pvt. Ltd. 

NCRM, unit of MediNippon Healthcare Pvt. Ltd. is an Indo-Japan healthcare organization established with the objective of developing solutions in healthcare based on innovative Japanese technologies, products and scientific expertise through inter-disciplinary research among a global network of physician-scientists with expertise in broad range of domains from agriculture to Zoology, including biomaterials and tissue engineering. Since 2002, this mission has yielded many path-breaking solutions in healthcare, including some reaching clinical stage. 

About GN Corporation Co. Ltd. 

GN Corporation Co. Ltd., Japan, headquartered in Kofu, Yamanashi, has built an interdisciplinary translational research network bringing together physicians, scientists, engineers, academic institutions and industry partners across countries. For nearly two decades, GN Corporation’s approach has focused on identifying promising basic-science technologies, unique biomaterials and healthcare innovations particularly those developed or available in Japan and matching them with unmet clinical needs. 

About SMC Laboratories, Inc. 

SMC Laboratories, Inc., Japan, is a specialized preclinical contract research organization with expertise in disease models and preclinical study design. SMC supports pharmaceutical and biotechnology research by providing preclinical platforms that facilitate translational drug development. 

Webinar Details

Date: 21 August 2026
Time: 8:00–9:00 AM JST

United States: 20 August 2026
4:00–5:00 PM PDT | 7:00–8:00 PM EDT

Format: Online | Free of Charge

Registration link: Watch the webinar  

Co-hosted by: SMC Laboratories, Inc., Japan & GN Corporation Co. Ltd. 

Media & Collaboration Enquiries 

NCRM, A Unit of MediNippon Healthcare Pvt. Ltd. 
Chennai, India 
mail@medinippon.jp  

GN Corporation Co. Ltd. 
Kofu, Yamanashi, Japan 
info@gncorporation.com  

SMC Laboratories, Inc. 
Tokyo, Japan 
Email: sato@smclab.co.jp 

Image: Left: Dr. Suryaprakash, presenting the encouraging outcome of BHES-HAUS for male urethral stricture in AUA 2026 (American Urological Association Annual meeting 2026). Right: STAR-MING implant as facial filler and breast implant is estimated to have a global market potential of 3.0 Billion USD as per market research reports.

DMI group of institutes in India, Tanzania, Malawi and Zambia to start basic to translational research

August 20, 2025

A MoU for translational research in managing corneal blindnesswas signed among Kanyakumari Medical Mission Research Center (KMMC), Muttom, a nodal institute of DMI foundation in southern most part of India, their associate St. Joseph University in Dar-Es-Salaam, Tanzania, GN Corporation, Japan, their associates NCRM & Medinippon, along with Be Well Hospitals, Chennai, India and Light and Light Ventures, London, UK. In Phases, a Centre of Excellence (CoE) for Regenerative Medicineto translate basic science developments to clinical solutions will be set up in KMMC taking technological guidance from Japanese physician-scientists.

St. Joseph University in Dar-Es-Salaam, Tanzania, DMI St. Eugene University in Lusaka, Zambia, DMI St. John the Baptist University, Mangochi, Malawi to jointly conduct academic and translational research with the CoE in KMMC to develop regenerative medicine solutions for managing locally prevalent healthcare problems.

Please visit below sites for related research papers;

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840311

https://doi.org/10.1080/02713683.2023.2180039

07 Apr 2025

The Bees-Haus method (Buccal epithelium Expanded and Encapsulated in Scaffold; Hybrid Approach to Urethral Stricture) of autologous buccal mucosal cell based therapy, earlier reported in India in collaboration with NCRM, has now moved to a clinical application in Japan.

Please visit Businesswire https://businesswire.com/news/home/20250330565540/en/ for more details.

Published in Nature Scientific Reports

01 Mar 2025

neu REFIX® exo-polysaccharide Beta glucan improves Dystrophin in diaphragm, IGF-1 and muscle regeneration markers CD44, MYH3 in Duchenne Muscular Dystrophy model in our research supported by Kochi University, Kyushu University of Medical Sciences and clinicians and scientists in India and Japan.

Please visit https://doi.org/10.1038/s41598-025-92258-4 for details of the study.

Sri Ramachandra Institute team triumphs in the FCQ of NCRM NICHE 2024

02 Dec 2024

Winners of the XIX Fujio Cup Quiz at NCRM NICHE 2024, Zainab Shabbir Rasheed and Saiganesh Venkatesan, posing with the Fujio Cup, joined by Mr. V.R. Venkataachalam, Chancellor, Sri Ramachandra Institute of Higher Education and Research – SRIHER, and Dr. A. Sumathy, Professor and Head, Department of Biomedical Sciences, SRIHER (Left).

A global recognition to our 16-year long research outcome!

30 Nov 2024

In the Genito-Urinary Reconstructive Surgeons (GURS) Masterclass 2024 conducted in United Kingdom, Dr Masayuki Shinchi　and Dr Akio Horiguchi presented the BEES-HAUS autologous cell therapy for male urethral stricture, and were awared the best poster prize.

The basic study started in 2008, through human and animal buccal tissue dervied cells cell culture standardization, pre-clinical and pilot clinical studies now having been recognised in the prestigious international forum, would add further strength to the team in moving forward to make this a routine clinical procedure to imporve the quality of life of patients ailing with urethral stricture.

Please see the link below for more details.

https://www.linkedin.com/feed/update/urn:li:activity:6969439001384558592

Clinical study results of Neu REFIX B-glucans & research updates by Dr. K. Raghavan

06 Oct 2024

Dr. Raghavan, Pediatric Neurologist and first author of the clinical study using Neu REFIX (https://www.sciencedirect.com/science/article/pii/S2667242123000556) gave an update on the ongoing research both clinical and pre-clinical (https://www.nature.com/articles/s41598-023-44330-0) and answered the questions by delegates.

Neu REFIX pre-clinical studies in mdx mice @ AOMC-JMS 2024

05 Oct 2024

Disease modifying approach in managing Duchenne Muscular Dystrophy with Neu REFIX Beta 1,3-1,6 Glucans was presented at the Joint Conference of The 22nd Annual Meeting of Asian and Oceanian Myology Center and The 10th Annual Meeting of Japan Muscle Society; 14, September 2024; Pre-clinical studies using mdx mice yielding reduction in inflammation and fibrosis and decline in fatigue explained; Available to watch in YouTube:

At the MENA Conference on Rare Diseases to be held in Abu Dhabi from May 16, 2024

19 April 2024

Safety and efficacy of our beta-glucan product, “neu REFIX®“, will be presented at the MENA Conference on Rare Diseases to be held in Abu Dhabi from May 16, 2024.

The MENA Rare Diseases Conference brings together experts from various medical fields for presentations, workshops, and group meetings on rare diseases, as well as the latest developments in the diagnosis and treatment of rare diseases and medical and support services for patients. We will be presenting evidence of “Neu-Refix” in Duchenne muscular dystrophy, both in mdx mice pre-clinically and clinically in patients with diagnosis of DMD, BMD and LGMD.

For more information on the conference, please click here.
https://menararediseases.com/